Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, April 26, 2025

Effectiveness of Transcarotid vs Transfemoral Carotid Stenting for Stroke Prevention

 Why do this? Verify the Circle of Willis is complete and close the offending artery. No complications from stenting or TCAR. I'm not medically trained, so ask your doctor EXACTLY WHY THEY WANT TO DO THESE PROCEDURES! Revenue generation I bet. And I bet you don't get a guarantee of no complications; that tells you about their confidence in these procedures!

Like other types of carotid revascularization, TCAR carries a risk of:
  • Injury of your carotid artery.
  • Bleeding around your neck wound.
  • Swelling around the cut in your neck.
  • Nerve damage.
  • Stroke.
  • Heart attack.
  • Death.


Here is why your doctor needs to GUARANTEE NO complications from stenting!

Effectiveness of Transcarotid vs Transfemoral Carotid Stenting for Stroke Prevention

Key Points

Question  What is the comparative risk of stroke after transcarotid artery revascularization (TCAR) vs transfemoral carotid artery stenting (TF-CAS) for patients with carotid artery stenosis?

Findings  In this comparative effectiveness study of 5798 asymptomatic and 4721 symptomatic patients who underwent carotid stenting, TCAR was associated with a lower risk of stroke than was TF-CAS. This finding was consistent in both asymptomatic and symptomatic patients and was durable over a 3-year interval.

Meaning  With no completed or enrolling randomized clinical trial to evaluate TCAR, these comparative stroke risk results can inform future procedure choice for patients who are considering carotid artery stenting.

Abstract

Importance  The effectiveness of surgical transcarotid artery revascularization (TCAR) compared with percutaneous transfemoral carotid artery stenting (TF-CAS) for stroke prevention beyond the periprocedural period is poorly quantified.

Objective  To compare the risk of stroke after TCAR vs TF-CAS.

Design, Setting, and Participants  This retrospective cohort study used data from the Vascular Implant Surveillance and Outcomes Network (VISION), a procedural registry linked to Medicare claims data that captures clinical, procedural, and outcome data on patients who underwent carotid stenting. Patients who underwent TCAR or TF-CAS between October 1, 2016, and December 31, 2019, and were captured in the VISION database were included. Data were analyzed between January and June 2024.

Exposure  Type of carotid stenting (TCAR vs TF-CAS).

Main Outcomes and Measures  The primary outcomes were any stroke, including both periprocedural and during follow-up, defined using a validated claims code list, and death. Asymptomatic and symptomatic patients were analyzed separately. Kaplan-Meier analysis was used to calculate the cumulative incidence of the outcomes, and a multivariable Cox proportional hazards model was used to determine hazard ratios (HRs).

Results  There were 5798 asymptomatic patients (mean [SD] age, 74.6 [7.7] years; 3631 male [62.6%]; 3482 underwent TCAR; 2316 underwent TF-CAS) and 4721 symptomatic patients (mean [SD] age, 74.2 [8.3] years; 2969 male [62.9%]; 2377 underwent TCAR; 2344 underwent TF-CAS) who underwent carotid stenting. Patients who underwent TCAR were older, more likely to be female, and less likely to have had a prior ipsilateral carotid revascularization procedure. Among asymptomatic patients, the Kaplan-Meier 3-year risk of stroke was lower after TCAR (5.1%; 95% CI, 3.0%-7.1%) than TF-CAS (9.2%; 95% CI, 7.7%-10.7%) (log-rank P < .001). The composite 3-year stroke or death risk after TCAR was 22.6% (95% CI, 18.8%-26.3%), compared with 31.4% (95% CI, 28.3%-34.3%) after TF-CAS (log-rank P < .001). Compared with TCAR, the adjusted HR of stroke after TF-CAS among asymptomatic patients was 1.69 (95% CI, 1.25-2.28; P < .001). Among patients with symptomatic carotid stenosis, the 3-year stroke risk was also lower for TCAR (16.6%; 95% CI, 12.1%-20.9%) than for TF-CAS (20.9%; 95% CI, 17.5%-24.1%) (log-rank P < .001). The composite 3-year stroke or death risk after TCAR was 35.9% (95% CI, 30.1%-41.2%), compared with 41.5% (95% CI, 37.6%-45.1%) after TF-CAS (log-rank P < .001). Compared with TCAR, the adjusted HR for stroke after TF-CAS among symptomatic patients was 1.42 (95% CI, 1.17-1.73; P < .001). Sensitivity analyses yielded similar results.

Conclusions and Relevance  In this comparative effectiveness study, TCAR was associated with a lower risk of stroke than TF-CAS. This finding was consistent in both asymptomatic and symptomatic patients and durable over a 3-year interval. These findings can inform procedure choices for patients considering carotid artery stenting.

More at link.

No comments:

Post a Comment